Halozyme (HALO) outlook: acquisitions extend IP beyond 2027, royalties are set to top $1B in 2026, and shares look discounted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results